An mRNA shot helped prevent relapse in high-risk melanoma patients.
Source link
Tags: Andrew Allen, Biology, Biotechnology Services, Business, Business/Consumer Services, C&E Industry News Filter, Cancer, Cancer Drugs, chemotherapy, Chemotherapy/Radiotherapy/Immunotherapy, consumer services, Content Types, corporate, Corporate/Industrial News, development, diagnostic, Diagnostic/Medical Research Services, Eliav Barr, Factiva Filters, general news, Gritstone bio, GRTS, Health, healthcare, Healthcare Support Services, Healthcare/Life Sciences, humanities, Immunizations, immunotherapy, industrial news, Jeffrey Weber, life sciences, Medical Conditions, Medical Research, Medical Research Services, medical treatments, Medical Treatments/Procedures, medications, Merck, Moderna, MRK, MRNA, new product, New Product/Service Testing, new products, New Products/Services, Nina Bhardwaj, Pharmaceuticals, political, Political/General News, procedures, products, Products/Services, radiotherapy, research, Research/Development, sciences, Sciences/Humanities, Scientific Research Services, service testing, services, Skin Cancer, specialized drugs, Specialized Drugs/Medications, Stephen Hoge, SYND, Vaccines, WSJ-PRO-WSJ.com, wsjhealth
